• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Upstream Bio Inc.

    3/12/25 7:15:34 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UPB alert in real time by email
    S-8 1 upb_s-8_2025_evergreen.htm S-8 S-8

     

     

    As filed with the Securities and Exchange Commission on March 12, 2025

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

     

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

    Upstream Bio, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    38-4187694

    (State or other jurisdiction of
    incorporation or organization)

    (I.R.S. employer
    identification no.)

    890 Winter Street, Suite 200

    Waltham, MA

    (Address of principal executive offices)

    02451

    (Zip Code)

     

    Upstream Bio, Inc. 2024 Stock Option and Incentive Plan
    (Full title of the plan)

    E. Rand Sutherland, M.D.
    Chief Executive Officer

    Upstream Bio, Inc.
    890 Winter Street, Suite 200

    Waltham, MA 02451

    (Name and address of agent for service)

    (781) 208-2466

    (Telephone number, including area code, of agent for service)

     

    Copies to:
    Gabriela Morales-Rivera
    William D. Collins

    Kathryn W. Clerici
    Goodwin Procter LLP
    100 Northern Avenue

    Boston, Massachusetts 02210
    (617) 570-1000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


     

    EXPLANATORY NOTE

    Pursuant to General Instruction E of Form S-8, Upstream Bio, Inc. (the “Registrant”) is filing this registration statement with the U.S. Securities and Exchange Commission (the “Commission”) to register 2,680,169 additional shares of the Registrant’s common stock, par value $0.001 per share (“Common Stock”), available for issuance under the Registrant’s 2024 Stock Option and Incentive Plan (the “Plan”), pursuant to the evergreen provisions of the Plan.

    This Registration Statement incorporates by reference the contents of the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on October 11, 2024 (File No. 333-282614) (the “Earlier Registration Statement”) related to the Plan, except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the Earlier Registration Statement are presented herein.

     

    Part II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

    The exhibits to this Registration Statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.

    EXHIBIT INDEX

     

     

     

    Exhibit
    No.

     

    Description

     

     

    4.1

     

    Third Amended and Restated Certificate of Incorporation of Upstream Bio, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-42366) filed on October 15, 2024).

     

     

    4.2

     

    Second Amended and Restated Bylaws of Upstream Bio, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-42366) filed on October 15, 2024).

     

     

    4.3

     

    Amended and Restated Investors’ Rights Agreement, among the Registrant and certain of its stockholders, dated June 6, 2023 (incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-282197) filed on September 18, 2024).

     

     

    5.1*

     

    Opinion of Goodwin Procter LLP.

     

     

    23.1*

     

    Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.

     

     

    23.2*

     

    Consent of Goodwin Procter LLP (included in Exhibit 5.1).

     

     

    24.1*

     

    Power of Attorney (included on signature page).

     

     

    99.1

     

    Upstream Bio, Inc. 2024 Stock Option and Incentive Plan and form of award agreements thereunder (incorporated by reference to Exhibit 10.2 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-282197) filed on October 7, 2024).

     

     

    107*

     

    Filing Fee Table.

     

    * Filed herewith.

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Massachusetts, on this 12th day of March, 2025.

    UPSTREAM BIO, INC.

    By:

     

    /s/ E. Rand Sutherland

     

     

    Name: E. Rand Sutherland, M.D.

    Title: Chief Executive Officer

     

    POWER OF ATTORNEY AND SIGNATURES

    Each individual whose signature appears below hereby constitutes and appoints each of E. Rand Sutherland, M.D. and Michael Paul Gray, M.B.A. as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    Name

    Title

    Date

    /s/ E. Rand Sutherland

    Chief Executive Officer and
    Director

    (Principal Executive Officer)

    March 12, 2025

    E. Rand Sutherland, M.D.

    /s/ Michael Paul Gray

    Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

    March 12, 2025

    Michael Paul Gray, M.B.A.

    /s/ Ronald C. Renaud, Jr.

    Director and Chairman

    March 12, 2025

    Ronald C. Renaud, Jr., M.B.A.

    /s/ Daniella Beckman

    Director

    March 12, 2025

    Daniella Beckman

    /s/ Erez Chimovits

    Director

    March 12, 2025

    Erez Chimovits, M.B.A., M.Sc.

    /s/ H. Edward Fleming, Jr.

    Director

    March 12, 2025

    H. Edward Fleming, Jr., M.D.

    /s/ Liam Ratcliffe

    Director

    March 12, 2025

    Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A.

    /s/ Marcella Kuhlman Ruddy

    Director

    March 12, 2025

    Marcella Kuhlman Ruddy, M.D., M.S.

     

     

     


    Get the next $UPB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UPB

    DatePrice TargetRatingAnalyst
    11/5/2024$75.00Overweight
    Piper Sandler
    11/5/2024$38.00Overweight
    JP Morgan
    11/5/2024Outperform
    William Blair
    11/5/2024Buy
    TD Cowen
    More analyst ratings

    $UPB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Sutherland Everett Rand

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      2/7/25 5:32:21 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CFO and COO Gray Michael

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      2/7/25 5:31:01 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Business Officer Houghton Adam

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      2/7/25 5:29:56 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chimovits Erez bought $14,025,000 worth of shares (825,000 units at $17.00) and converted options into 3,609,789 shares (SEC Form 4)

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      10/17/24 4:19:30 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Orbimed Advisors Llc bought $14,025,000 worth of shares (825,000 units at $17.00) and converted options into 3,609,789 shares (SEC Form 4)

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      10/17/24 4:17:52 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Ai Upstream Llc bought $19,975,000 worth of shares (1,175,000 units at $17.00) and converted options into 4,319,410 shares (SEC Form 4)

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      10/17/24 4:05:04 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Upstream Bio Appoints Stacy Price as Chief Technology Officer

      WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls (CMC) pr

      5/20/25 7:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

      – Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in the third quarter of 2025 – – Top-line data from Phase 2 clinical trial of verekitug in patients with severe asthma now expected in the first half of 2026 – – First patient in Phase 2 clinical trial of verekitug in patients with chronic obstructive pulmonary disease to be dosed in mid-2025 – WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the first quarter ended Mar

      5/6/25 7:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      – Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 – – Completed upsized IPO with gross proceeds of approximately $293 million, extending runway through 2027 – WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a summary of recent business highlights. Upstream is developing verekitug, the only monoclonal

      3/12/25 7:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    SEC Filings

    See more
    • SEC Form 10-Q filed by Upstream Bio Inc.

      10-Q - Upstream Bio, Inc. (0002022626) (Filer)

      5/6/25 7:10:23 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Upstream Bio, Inc. (0002022626) (Filer)

      5/6/25 7:05:10 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Upstream Bio Inc.

      DEFA14A - Upstream Bio, Inc. (0002022626) (Filer)

      4/17/25 4:10:03 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on Upstream Bio with a new price target

      Piper Sandler initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $75.00

      11/5/24 6:29:20 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan initiated coverage on Upstream Bio with a new price target

      JP Morgan initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $38.00

      11/5/24 6:28:28 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on Upstream Bio

      William Blair initiated coverage of Upstream Bio with a rating of Outperform

      11/5/24 6:28:02 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Leadership Updates

    Live Leadership Updates

    See more
    • Upstream Bio Appoints Stacy Price as Chief Technology Officer

      WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls (CMC) pr

      5/20/25 7:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio Appoints Allison Ambrose as General Counsel

      WALTHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company has appointed Allison Ambrose, J.D. as General Counsel. Ms. Ambrose is a senior legal leader with more than 15 years of experience providing counsel on a wide range of matters including corporate governance, securities law and compliance, and capital markets and corporate development transactions. Ms. Ambrose will oversee all aspects of Upstream's legal function and join the Company's executive leadership team. "I am thrilled to welcome Allison to

      12/17/24 8:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Upstream Bio Inc.

      SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

      11/7/24 9:24:55 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Upstream Bio Inc.

      SC 13D - Upstream Bio, Inc. (0002022626) (Subject)

      10/22/24 4:06:27 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Upstream Bio Inc.

      SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

      10/18/24 6:10:56 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care